Infant Formula Requirements: Current Good Manufacturing Practice, Quality Control Procedures, and Quality Factors
The most drug-like food regime FDA operates: CGMP, quality-control procedures, mandatory audits, quality factors, and records/reports for infant formula, rebuilt by the 2014 final rule under the FD&C Act's dedicated infant-formula section. It requires controls against microbiological contamination — including Cronobacter and Salmonella testing of powdered formula — nutrient content assurance through the shelf life, and demonstration of quality factors such as normal physical growth.
What this does not cover
stated in the document's own scope- Covers infant formula manufacture; nutrient specifications, labelling, and exempt-formula rules are in the companion Part 107.
- A food regulation under FD&C section 412: infant formula is not a drug, and drug CGMP (Part 211) does not apply — the resemblance is architectural, not legal.
- General food facilities follow Part 117; Part 106's batch-level nutrient assurance, audits, and quality factors are specific to infant formula.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 106 is the infant-formula quality regulation — the closest thing in US food law to pharmaceutical GMP. Rebuilt by the 2014 final rule, it requires current good manufacturing practice specific to infant formula, including controls designed to prevent adulteration by micro-organisms — with finished-product testing of powdered formula for Cronobacter and Salmonella — and to preserve required nutrient content through the shelf life. On top of CGMP sit quality-control procedures assuring that every batch meets nutrient specifications, a mandatory audit programme against a written audit plan, quality factors requiring demonstration that formulas support normal physical growth and adequate protein quality, and records, reports, and notification duties, including for reformulations and new formulas.
Scope & applicability
Manufacturers of infant formula for the US market, including non-exempt and (with modifications) exempt formulas. Statutory basis is section 412 of the FD&C Act; nutrient specifications and labelling sit in the companion Part 107.
Legal basis & how it acquires force
A regulation issued under section 412 of the FD&C Act — the infant-formula provisions created by the Infant Formula Act of 1980 and strengthened in 1986 — and implemented in current form by the interim final rule of February 2014, confirmed by the final rule of 10 June 2014. Nutrient requirements, labelling, and exempt-formula provisions sit in the companion Part 107; an infant formula that fails Part 106/107 requirements is adulterated under section 412.
Document structure
| Part | Covers |
|---|---|
| Subpart A — General provisions | Scope, definitions, and applicability, including treatment of exempt infant formulas |
| Subpart B — Current good manufacturing practice | Production and in-process controls, prevention of microbiological adulteration (including Cronobacter and Salmonella testing of powdered formula), and equipment and personnel controls |
| Subpart C — Quality control procedures | Batch-level assurance that each nutrient is present at the required level through shelf life |
| Subpart D — Conduct of audits | Regular audits against a written audit plan covering CGMP and quality-control compliance |
| Subpart E — Quality factors | Demonstration of normal physical growth and sufficient biological quality of protein |
| Subparts F–G — Records, reports, and notifications | Record-keeping, reporting, and registration/submission/notification duties for new and reformulated formulas |
Key requirements
- CGMP controls across production, including prevention of microbiological and nutrient-loss adulteration (Subpart B)
- Quality-control procedures assuring nutrient levels in each batch through shelf life (Subpart C)
- Regular audits against a written audit plan (Subpart D)
- Quality factors, including demonstration of normal physical growth and protein quality (Subpart E)
- Records, reports, and pre-market notification duties for new and reformulated formulas (Subparts F–G)
Implementation tips
- Treat Part 106 as a pharmaceutical-grade quality system applied to a food: batch-level nutrient assurance and finished-product micro testing are enforceable requirements, not certification extras
Revision notes
The interim final rule of February 2014 was confirmed by the final rule of 10 June 2014, establishing the current CGMP, quality-control, audit, and quality-factor framework.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 106 imports pharmaceutical-style quality thinking into food law: batch release against specifications, finished-product microbiological testing, audit programmes, and pre-market notification are structurally closer to drug CGMP (21 CFR 211) than to the general food CGMP of Part 117 — which is why infant formula is often described as the most drug-like food regime FDA runs. Internationally, Codex standards for infant formula and national implementations cover the same product class with compositional standards; the CGMP/quality-factor architecture is a US construction.
21 CFR Part 106: frequently asked questions
Quick answers to common questions about 21 CFR Part 106.
Why is infant formula regulated more strictly than other foods?
Because it may be the sole source of nutrition for a vulnerable population. Section 412 of the FD&C Act, added by the Infant Formula Act of 1980 after nutrient-deficiency incidents, mandates specific nutrients, CGMP, quality control, and notification duties — and Part 106 implements them with batch-level assurance and finished-product pathogen testing.
What pathogen testing does Part 106 require?
Powdered infant formula must be tested for Cronobacter species and Salmonella species as part of the CGMP controls against microbiological adulteration, alongside the environmental and process controls that prevent contamination in the first place.
What are "quality factors" in Part 106?
Requirements that an infant formula actually supports healthy infants: demonstration of normal physical growth (typically through a growth-monitoring study) and sufficient biological quality of protein. They sit above nutrient content — a formula can meet every specification and still fail quality factors.
When did the current Part 106 take effect?
FDA issued an interim final rule in February 2014 and confirmed it with the final rule of 10 June 2014, establishing the current CGMP, quality-control, audit, quality-factor, and notification framework.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.